VivoSeq
Oncology

Non-Hodgkins Lymphoma

101

Pipeline Programs↗

3

Active Trials↗

49

Companies Involved↗

Non-Hodgkins Lymphoma is a highly competitive landscape with 101 programs across 49 companies. The most active players are Horizon Therapeutics Ireland DAC, Regeneron, Amgen. 52 therapies are approved with 11 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

69/100

Pipeline Velocity

0/100

Mech. Concentration

6/100

Completion Rate

75/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

H

Horizon Therapeutics Ireland DAC

1 program

Phase 1Regeneron logo

Regeneron

1 program

Phase 1Amgen logo

Amgen

3 programs

Phase 2T

TG Therapeutics, Inc.

2 programs

Phase 2Incyte logo

Incyte

2 programs

Phase 2I

Incyte Biosciences Japan GK

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical6

Brentuximab Vedotin

Pfizer

Idelalisib

Gilead

Bendamustine Hydrochloride

SymBio Pharmaceuticals

Doxorubicin Hydrochloride

Gynecologic Oncology Group

Atezolizumab

Roche

Phase 19

Ocrelizumab

Roche

Glofitamab

Roche

Mitoxantrone Hydrochloride

Pfizer

Interferon Gamma-1b

Horizon Therapeutics Ireland DAC

Loncastuximab Tesirine

Akero Therapeutics

Phase 223

Aldesleukin

Iovance Biotherapeutics, Inc.

Blinatumomab

Amgen

Epcoritamab

Genmab

Tafasitamab

Incyte

Siltuximab

RECORDATI GROUP

Phase 311

Asparaginase

Dutch Childhood Oncology Group

Polatuzumab Vedotin

Roche

Obinutuzumab

Roche

Enzastaurin

Eli Lilly

Mosunetuzumab

Roche

Approved52

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Panobinostat

SecuraBio

Thioguanine

Akero Therapeutics

Venetoclax

AbbVie

Ifosfamide

Baxter Healthcare Corporation

Analysis

Modality Breakdown

69%

Small molecule

73 of 106 classified programs — the dominant modality here.

31%ALL OTHERSMonoclonal antibody2019%Protein / enzyme77%Antibody–drug conjugate44%Cell therapy22%

Small molecule leads; the ring shows all 106 classified programs, each share of the total. Modality classified for 99% of 107 pipeline programs.

Analysis

Trial Status

12

clinical trials

Completed6 · 50%
Terminated2 · 17%
Active, not recruiting2 · 17%
Unknown status1 · 8%
Recruiting1 · 8%

Clinical Trials

Trial Activity

12 trials

A Phase 2 Study of Acalabrutinib With DA-EPOCH-R or R-CHOP for Patients With Untreated Diffuse Large B-cell Lymphoma
Recruiting·National Cancer Institute (NCI)·Phase 2·NCT04002947·132 enrolled
To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)
Active, not recruiting·IIncyte Biosciences Japan GK·Phase 1/2·NCT04661007·72 enrolled
An Open-Label, Multi-Center, Phase IB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin (Plus a Single Pre-Treatment Dose of Obinutuzumab) in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Active, not recruiting·Roche logoRoche·Preclinical·NCT03533283·211 enrolled
Study to Assess the Pharmacokinetics and Pharmacodynamics of GSK461364 in Subjects With Non-Hodgkins Lymphoma
Completed·GSK logoGSK·Phase 1·NCT00536835·41 enrolled
Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma
Completed·Pfizer logoPfizer·Phase 2·NCT00868608·81 enrolled
Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma
Completed·GSK logoGSK·Phase 3·NCT00268983·14 enrolled
LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma
Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00610883·17 enrolled
Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed Non-Hodgkins Lymphoma
Completed·—·Phase 2·NCT00166439·50 enrolled
COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients
Completed·Bayer logoBayer·Phase 1·NCT02253420·51 enrolled
Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
Terminated·TTG Therapeutics, Inc.·Phase 2/3·NCT02793583·710 enrolled
Dose Escalation and Expansion Study of CPO107 for Patients with Advanced CD20-positive Non-Hodgkins Lymphoma
Terminated·CConjupro Biotherapeutics, Inc.·Phase 1/2·NCT04853329·7 enrolled
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma
Unknown status·SShanghai Ming Ju Biotechnology Co., Ltd.·Phase 2·NCT04089215·82 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)